According to Zhitong Finance App News, Zhixiang Jintai (688443.SH) released its report for the third quarter of 2026. The company achieved operating income of 778 million yuan in the first three quarters, an increase of 274.75% over the previous year; net loss attributable to shareholders of listed companies of 6.3835 million yuan; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 19.1051 million yuan; basic earnings per share -0.02 yuan.

^{In the first three quarters, the year-on-year increase in the company's revenue was mainly due to license revenue of 519 million yuan corresponding to the contract performance obligations of the GR1803 injection license agreement, and sales revenue of the company's first commercial product, Celikizumab Injection (Ginlisi®), which was 257 million yuan, a significant increase over the same period last year.}

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.